• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    PCI Pharma Services

    Baxter BioPharma Solutions

    Syngene

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Quotient Sciences

    Emergent BioSolutions

    PCI Pharma Services

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Modeling & Simulation for Drug Development & Formulation

    A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.

    Modeling & Simulation for  Drug Development & Formulation
    Modeling & Simulation for  Drug Development & Formulation
    Figure 1. The role of IVIVC becomes more evident as an important tool in drug development to enhance product and process understanding with the ultimate goal of ensuring consistent performance throughout the product’s life cycle. IVIVC studies are encouraged. – US FDA
    Modeling & Simulation for  Drug Development & Formulation
    Figure 2. The BCS classifies drugs in four categories. These factors will drive the methodology options, with Class I being the most straightforward and statistical.
    Related CONTENT
    • Ascendia Pharmaceuticals Poised for Expansion
    • Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Recro Pharma Expands Business Development Team
    • Crystec Launches New R&D Center in China
    Nathan Teuscher and Nikunjkumar Patel , Certara03.07.17
    Modeling and simulation (M&S) has already profoundly impacted drug development and formulation. It is used in 90% of all U.S. Food and Drug Administration (FDA) drug approvals. M&S can influence every phase of the drug development process, including informing commercial decisions about the benefits of bringing a specific drug to market. It can be employed to compare the safety and efficacy of drug candidates; select dose and dose regimen; and identify potential drug-drug and drug-food interactions. M&S can be used in lieu of specific clinical trials, and of importance to those involved in drug formulation, leveraged to demonstrate virtual bioequivalence and obtain biowaivers.

    Formulation science is an iterative process that can benefit from the ‘predict, learn, confirm and apply’ paradigm underpinning M&S. That paradigm can support and strengthen the overall formulation strategy and inform the numerous alternate formulations that will be developed throughout the development cycle. Formulation selection can profoundly impact drug release, absorption, and metabolism, altering the drug’s pharmacokinetic profile and its pharmacodynamic response.

    In short, M&S can predict the in vivo performance of drug products. Therefore, its use can improve formulation strategy by aiding scientists in designing a rational and cost-effective approach to formulation development (see Figure 1).

    What is modeling and simulation?
    M&S is an integrative science, which incorporates relationships between disease and biological pathways, drug characteristics, and individual variability, and leverages existing knowledge to guide future research. M&S is an invaluable drug development and formulation tool whose use is actively encouraged by global regulators.

    An in-vitro in-vivo correlation (IVIVC) has been defined by the FDA as “a predictive mathematical model describing the relationship between an in-vitro property of a dosage form and an in-vivo response.” The U.S. Pharmacopoeia (USP) defines IVIVC as establishing a rational relationship between a biological property produced by a dosage form, and a physiochemical property of the same dosage form.

    Developing and optimizing a new drug formulation may involve changes in the drug composition, manufacturing process, use and type of equipment, or batch size. These changes, which can occur often, trigger the need to conduct bioavailability studies to demonstrate ‘equivalence’ between the original accepted formulation and the new one. IVIVC is a biopharmaceutical tool used in drug development and formulation optimization to demonstrate that equivalence. 

    IVIVC: Accelerating formulation development and saving costly studies
    IVIVC technology allows formulation and manufacturing professionals to understand how dissolution parameters affect in vivo drug performance. Dissolution testing is required for all solid oral dosage forms and is used in all phases of development for product release and stability testing. This key analytical test can detect physical changes in an active pharmaceutical ingredient and in the formulated product.

    This information can be determined quickly, under inexpensive, controlled lab conditions, to serve as a surrogate for the in vivo drug behavior rather than through expensive and time-consuming animal or human bioavailability or bioequivalence (BA or BE) studies. Each BA/BE study replaced by IVIVC analysis can shorten the development cycle by months and save hundreds of thousands of dollars. At the same time, IVIVC gives scientists the requisite knowledge to tweak a drug’s formulation to improve its in vivo performance with fewer iterations and false starts.

    There are many instances during a drug’s life cycle when its bioequivalence may need to be established. Its formulation may have been changed to alter its release timing, improve its solubility and absorption, reduce manufacturing costs, extend its shelf life, prevent adverse events such as an upset stomach, improve its taste or smell, or hold the tablet together better. New formulations may be required multiple times during a drug’s life cycle because of changes to the manufacturing supplies, processes, dosage forms, or other factors. In many of these instances, IVIVC can be used to gain a biowaiver for the product.

    Modeling and simulation for IVIVC
    There are two main types of M&S for IVIVC, which when used in a complementary way are considered ‘best practice’.

    Conventional (statistical) IVIVC. This method uses deconvolution methods such as Wagner-Nelson, Loo-Riegelman, numerical deconvolution and modified deconvolution to estimate the rate of input of a drug into the systemic circulation of observed plasma drug concentrations from the oral formulation.

    The FDA guidance for, “Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations,” mentions four levels of IVIVC (A, B, C, and D) based on the correlation’s ability to reflect accurately the complete plasma drug concentration-time profile resulting from administering the given dosage form. Level A represents the highest correlation—a point-to-point statistical relationship between the in vitro dissolution rate and in vivo input rate. This approach is used most often to attain biowaivers. 

    While conventional IVIVC is the gold standard for drugs displaying a linear relationship between absorption and dissolution, today’s more complex drugs need alternative modeling approaches. FDA held a workshop in May 2016 where it brought together experts from industry, academia and the regulatory agency to address this need and evaluate mechanistic IVIVC as an evolving technology for drug formulation. During that workshop, the FDA shared its current thinking on mechanism-based absorption M&S and obtained public input on its future application for bioequivalence determination and other regulatory activities for oral drug products.

    Mechanistic IVIVC (PBPK). This approach considers separately the various mechanisms involved in drug absorption, such as transit time, gut wall permeability, gut wall metabolism, and hepatic first-pass metabolism from dissolution rate. By integrating the anatomical and physiological parameters of the gastrointestinal (GI) tract with the physicochemical properties of drug substances, mechanistic IVIVC provides scientists with valuable insights for designing and evaluating the performance and safety of new drug formulations. Mechanistic models provide them with a detailed understanding of the mechanisms involved in absorption and how critical they are for formulation.

    Mechanistic physiologically-based pharmacokinetic (PBPK) models, such as the Simcyp Simulator, can be used to estimate in vivo dissolution rather than just the systemic input rate, separately accounting for permeation, GI transit and first-pass elimination. This enables the IVIVC to be integrated with other model components to predict in vivo product performance across a specific patient population. Information on transporters and drug metabolic pathways can also be incorporated to model in vivo exposure for a specific body part or the blood.

    How to select the most appropriate IVIVC modeling method
    Oral drugs can be classified according to the Biopharmaceutics Classification System (BCS), which is based on the drug’s solubility and permeability. Established in the 1990s and adopted by the FDA in 2000, the BCS provides a regulatory framework for new drug formulations that includes setting dissolution specifications, supporting risk assessment, evaluating post-approval changes, and approving biowaivers. Additionally, the BCS provides a framework for drug development starting with candidate selection and moving to pre-formulation evaluation, solid form selection, and formulation strategies. 

    The body’s ability to absorb oral drug products varies according to physiological and physiochemical factors and the dosage form. The main physiological processes impacting in vivo dissolution and absorption within the GI tract are secretion, digestion, and absorption. Underlying those processes are factors including pH; fluid, electrolyte, peptide, protein and digestive enzyme levels; surface area; GI motility and transit time; and bile secretion. The key physiochemical properties of drug molecules are solid particle dissolution, ionization, and solubility. When evaluating dosage form, whether it be immediate, modified, extended or delayed release, the rate and amount of absorption are influenced by the drug design and dissolution profile.

    The IVIVC method selected depends on the type of product and the objectives of the modeling. With numerical approaches, inter- and intra-subject variability is noise. Including or excluding statistical covariates and/or modifying the study design can minimize that noise. The goal is correlating the in vivo and in vitro data.

    In contrast, when using a mechanistic approach, separating drug and formulation parameters from subject physiology variability allows associated variabilities to be estimated and projected. This provides an opportunity for population-level simulation and analysis. It also allows scientists to extrapolate from one physiological condition to another, allowing them to answer ‘what if’ questions or virtually assess untested clinical scenarios. Assuming that the IVIVC remains valid for alternate formulations or with other patient physiologies, scientists can expand their product understanding beyond the limits of the available IVIVC dataset and migrate into personalized medicine.

    Many new drug candidates are poorly soluble, which can severely limit their bioavailability. To ameliorate this issue, a widely used approach is formulating supersaturated drug solutions. However, supersaturated solutions risk precipitation, which can limit the intended benefits of this approach. To address this issue, the U.S. FDA recently awarded Certara’s Simcyp division a grant to develop a mechanistic modeling and simulation framework to predict the behavior of orally-dosed supersaturating drugs and drug products (see Figure 2).

    Strategic value of M&S in formulation
    The U.S. FDA, European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, and other global regulatory agencies encourage the use of IVIVC. They consider it an important drug development tool, which enhances product and process understanding, with the ultimate goal of ensuring consistent performance throughout the product’s life cycle.

    FDA recently published a paper, entitled, “Regulatory Experience with In Vivo In Vitro Correlations in New Drug Applications.” The authors discussed using IVIVC for pre-approval (bridging formulations to the pivotal BA/BE batch), and post-approval (formulation, manufacturing site, and process) changes to reduce the need for in vivo bioequivalence studies.

    They also stressed the value that IVIVC can provide by facilitating decision making during drug development, especially in light of the Quality by Design (QbD) paradigm. QbD, promoted by FDA and EMA, is the concept that product and process performance characteristics are scientifically designed to meet specific objectives, not merely empirically derived from performance of test batches. IVIVC is leveraged for three purposes:
    • Regulatory: As a surrogate for in vivo bioequivalence studies and to support attaining biowaivers; in lieu of certain in vivo experiments; to evaluate pre- and post-approval manufacturing changes; and to evaluate custom risk factors to guide post-marketing surveillance.
    • Drug development: To provide initial guidance and direction for early formulation development; to inform how and what is chosen for the in vitro release testing methods; to help understand PK variability so that scientists can design better bioequivalent studies and reduce sample sizes; to extrapolate data from healthy volunteers in BE studies to patients with GI conditions; to prioritize formulation efforts pertaining to product development, and oftentimes minimize the number of pilot studies required; to enhance drug product understanding during the development cycle; and to reduce regulatory uncertainty and gain product approval more quickly.
    • Formulation and manufacturing: To evaluate potential performance differences for modified release formulations; to test the impact of each component and assure quality control in formulation and reformulation; to reduce the number of bioequivalence studies required due to scale-up and post-marketing changes; and to bridge formulations to the pivotal BA/BE batch.
    Case Study: IVIVC on a compound with release rate specific bioavailability
    The challenge was developing an IVIVC model for a compound and formulation whose release rate, specific bioavailability, and non-linear relationships would not initially seem to support an IVIVC.

    The formulation under evaluation was a capsule containing four different types of delayed release beads. Each bead was characterized by a mean dissolution time (MDT) and a time lag (Tlag) and each of the seven formulations under study was comprised of a different ratio of each bead type.

    The data simulation model contained elements of stomach emptying, intestinal and colon transit, first-pass metabolism in the small intestine and multi-compartment pharmacokinetics. The simulations were done in three stages: simulating dissolution profiles, generating subject PK parameters from a multivariate log-normal distribution, and simulating individual plasma profiles using three kinetic compartments, two absorption compartments with transit times, and proportional error on observations.

    Using conventional IVIVC methodology with Phoenix IVIVC software, mean plasma profiles for four formulations—10-20 subjects per formulation—were deconvolved using the PK parameters relating to the intravenous kinetics of the compound. The generated series of fraction-absorbed profiles were then overlaid with the dissolution profiles. Reviewing this plot suggested that the slower formulations had greater bioavailability than the fastest release, and the slower the release, the greater the bioavailability.

    This meant that a simple model could not describe the data well, requiring a custom model to fit the nonlinearity of the compound. Since the Levy plot indicated two time scales, a bi-linear model was used with an initial lag consistent with a stomach emptying effect together with data representing intestinal transit time switching between phases.

    Inferences drawn from data exploration can guide IVIVC development. In this case, an initial model was proposed after analyzing two exploratory plots. Model refinement is motivated by consideration of physiological mechanisms and leads to a suitable IVIVC, used for regulatory purposes.

    Case Study: IVIVC using physiologically-based absorption modeling
    This project used mechanistic modeling to establish IVIVC for a controlled release formulation of topiramate. Topiramate’s bioavailability depends on the site of GI absorption. Specifically, topiramate exhibits higher bioavailability in the colon compared to the stomach. For example, a dosage can be designed wherein the delayed-release component contains less topiramate than the immediate-release component but that nonetheless achieves a blood plasma concentration equivalent to the immediate-release component. Alternatively, a dosage can be designed so that the delayed-release component contains an amount of topiramate equal to that of the immediate-release component yet would achieve a blood plasma concentration greater than that of the immediate-release component.

    To study this, a PBPK model was built using the Simcyp Advanced Dissolution Absorption and Metabolism (ADAM) model. Four formulations—slow, medium and fast release and oral—and multiple immediate release doses were studied, using clinical dataset, formulation and food-drug interaction data. The PBPK approach improved the predictive performance of the IVIVC model, producing a linear IVIVC.

    The discovery of the differential bioavailability of topiramate allows a more rational drug design based upon the specific therapeutic profiles to be achieved. IVIVC modeling facilitates these alternative formulations.

    Conclusion
    IVIVC M&S plays a strategic role throughout the drug development and formulation process. It allows sponsors to replace expensive, time-consuming BA/BE studies with more efficient, inexpensive IVIVC analyses, shaving months and hundreds of thousands of dollars off development. It also provides scientists with greater product insight, allowing them to change a drug’s formulation to improve both its in vivo performance and likelihood of regulatory success. 


    Nathan Teuscher, Ph.D., is the vice president of pharmacometric solutions at Certara.

    Nikunjkumar Patel, M.S. (Pharm), is a senior research scientist in Certara’s modelling and simulations group.
    Related Searches
    • Pre-Formulation
    • quality
    • Manufacturing
    • equipment
    Suggested For You
    Ascendia Pharmaceuticals Poised for Expansion Ascendia Pharmaceuticals Poised for Expansion
    Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    Sterling Pharma Solutions Acquires ADC Biotechnology Sterling Pharma Solutions Acquires ADC Biotechnology
    Recro Pharma Expands Business Development Team Recro Pharma Expands Business Development Team
    Crystec Launches New R&D Center in China Crystec Launches New R&D Center in China
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    RBQM Comes of Age: COVID as a Catalyst for Change RBQM Comes of Age: COVID as a Catalyst for Change
    Eloxx Pharmaceuticals Acquires Zikani Therapeutics Eloxx Pharmaceuticals Acquires Zikani Therapeutics
    On-Demand Webinar: Accelerated Timelines for Clinical Supply Manufacture On-Demand Webinar: Accelerated Timelines for Clinical Supply Manufacture
    SK Capital Completes Acquisition of BFS from Catalent Pharma Solutions SK Capital Completes Acquisition of BFS from Catalent Pharma Solutions
    CureVac, Celonic Enter COVID-19 Vax Mfg. Pact CureVac, Celonic Enter COVID-19 Vax Mfg. Pact
    Advanced Analytics Advancing Development of Genetic Vaccines Advanced Analytics Advancing Development of Genetic Vaccines
    Chime Biologics Expands CDMO Capabilities Chime Biologics Expands CDMO Capabilities
    Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise
    Piramal Pharma Solutions, Plus Therapeutics Ink MSA 
 Piramal Pharma Solutions, Plus Therapeutics Ink MSA 


    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Formulation Development
      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      A strong trend in drug substance and drug product biomanufacturing, as is for formulation, is that of increasing therapeutic complexity.
      Latika Bhonsle-Deeng, Rentschler Biopharma SE, and Konstantin Petropoulos, LEUKOCARE AG 10.14.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20


    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20

    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20


    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19

    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19


    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19

    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19

    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19


    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    The Honest Company Files for IPO
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login